WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%.

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

A 10 per cent tariff on exports could eat into China’s economic growth, putting Beijing’s 4.5 per cent target at risk, Morgan Stanley says.

A private report shows that China’s manufacturing industry expanded at the fastest pace in four months in March.

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/ ...